EGFR and neoplasm: Furthermore, irrespective of the number of baseline targeted lesions or total tumor diameter, the median depth of response was 0.5 to 0.7 in the anti-EGFR antibody group, 0.4 to 0.5 in the bevacizumab group, and 0.4 to 0.5 in the chemotherapy-alone group (Figure S1).